News

Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently... read more 

Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-04-2010
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants. ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. The two year follow up data... read more 

Board

Mark Wegter

Mr. Wegter became a member and chairman of our Supervisory Board in 2001. Mr. Wegter graduated from the Erasmus University of Rotterdam, The Netherlands with a degree in economics. In 1998, Mr. Wegter joined Life Sciences Partners,becoming a general partner in 2001. In that same year Mr. Wegter established Life Sciences Partners’ office in Munich, Germany.

Martijn Kleijwegt

Mr. Kleijwegt became a member of our Supervisory Board in 2006. Mr. Kleijwegt graduated from the University of Amsterdam, The Netherlands with a degree in economics. Mr. Kleijwegt founded Life Sciences Partners in 1998 and has been managing partner of Life Sciences Partners since that date.

Ekaterina Smirnyagina

Dr. Smirnyagina became a member of our Supervisory Board in 2007. Dr. Smirnyagina graduated from Moscow State University, Russia with a degree in biochemistry and obtained a PhD in cellular and molecular biology from the University of Wisconsin-Madison, USA. Dr. Smirnyagina joined Alta Partners in 2002 and became a venture partner in 2006.

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51